stockportfolio.pro
Avantor, Inc. (AVTR)
Healthcare · Medical Instruments & Supplies · NYSE
Avantor, Inc. revenue & earnings — last 9 fiscal years
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.25B | $5.86B | $6.04B | $6.39B | $7.39B | $7.51B | $6.97B | $6.78B | $6.55B |
| Gross profit | $432.80M | $1.82B | $1.92B | $2.08B | $2.50B | $2.60B | $2.36B | $2.28B | $2.14B |
| Net income | $-112.70M | $-86.90M | $37.80M | $116.60M | $572.60M | $662.30M | $321.10M | $711.50M | $-530.20M |
| Net margin | -9.0% | -1.5% | 0.6% | 1.8% | 7.8% | 8.8% | 4.6% | 10.5% | -8.1% |
Source: Avantor, Inc. SEC filings (10-K).
Explore 9 years of Avantor, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track AVTR in your portfolio →
About Avantor, Inc.
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, compound management, cleanroom control, monitoring, maintenance, and sanitization services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Avantor, Inc. — frequently asked questions
What is Avantor, Inc.'s revenue?
Avantor, Inc. (AVTR) reported revenue of $6.55B for fiscal year 2025, down 3.4% from the prior year, according to its SEC filings.
Is Avantor, Inc. profitable?
No — AVTR reported a net loss of $-530.20M in fiscal 2025.
What is AVTR's P/E ratio?
Avantor, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Avantor, Inc. growing?
AVTR's revenue grew at roughly 0.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Avantor, Inc.'s official SEC filings (10-K and 10-Q), covering 9 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.